When was Slate Medicines founded?

Slate Medicines was founded in 2026 and raised its 1st funding round within a year of its incorporation.

Where is Slate Medicines located?

Slate Medicines is headquartered in Raleigh, United States.

Who is the current CEO of Slate Medicines?

Neil Buckley of Slate Medicines. They have also founded 1 company.

How many employees does Slate Medicines have?

As of Sep 30, 2026, the latest employee count at Slate Medicines is 15.

Is Slate Medicines a funded company?

Slate Medicines is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Feb 17, 2026.

How much is Slate Medicines worth?

The latest valuation of Slate Medicines is $***** as of Sep 01, 2026.

When was the latest funding round of Slate Medicines?

Slate Medicines' latest funding was a $***** Series A round on Feb 17, 2026, with participation from 3 investors. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.57B in funding in 2026 to date.

Where does Slate Medicines rank among its competitors?

Slate Medicines ranks 94th amongst 317 active competitors, of which 81 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Quince Therapeutics, which secured $187M in May, 2026.

Who are the top competitors of Slate Medicines?

Slate Medicines' top competitors include argenx, Vor Biopharma and Xenon Pharmaceuticals. Among them, Quince Therapeutics secured the most recent funding round in May, 2026.

Slate Medicines - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutics for the treatment of migraine and other headache disorders. The company is focused on developing next generation therapeutics targeting PACAP for the treatment and prevention of migraine and other headache disorder

Key Metrics

Founded Year

2026

Location

Raleigh, United States

Stage

Series A

Total Funding

$130M in 1 round

Latest Funding Round

Series A, Feb 17, 2026, $*****

Post Money Valuation

$***** as on Sep 01, 2026

Investors

RA Capital Management & 2 more

Ranked

94^th among 317 active competitors

Employee Count

15 as on Sep 30, 2026

Similar Companies

Xenon Pharmaceuticals & 265 more

View Slate Medicines' full profile

Slate Medicines has raised a total funding of $130M over 1 round. Its latest funding round was a Series A round on Feb 17, 2026 for $*****. 3 investors participated in its latest round. Slate Medicines has 3 institutional investors.

Here is the list of recent funding rounds of Slate Medicines:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 17, 2026	3177730	Series A	5496459	6489574	9228414	4876906

Access funding benchmarks and valuations. Sign up today!

View details of Slate Medicines's funding rounds and investors

The founders of Slate Medicines is Neil Buckley. Neil Buckley is the CEO of Slate Medicines.

Here are the details of Slate Medicines' key team members:

Neil Buckley: Co-Founder & CEO of Slate Medicines.

View details of Slate Medicines's Founder profiles and Board Members

Slate Medicines' employee count trend

Slate Medicines has 15 employees as of Sep 26. Here is Slate Medicines's employee count trend over the years:

Employee count trend for Slate Medicines

Uncover Slate Medicines' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Slate Medicines include argenx, Vor Biopharma and Xenon Pharmaceuticals. Here is the list of Top 10 competitors of Slate Medicines, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	76/100
2nd	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	69/100
3rd	Xenon Pharmaceuticals 2000, Burnaby (Canada), Public	Developer of small molecule drugs against rare channelopathies	$85.7M	Fidelity Investments, Invesco & 14 others	64/100
4th	Radius Health 2003, Boston (United States), Acquired	Biopharmaceutical company focused on bone health and related therapeutic areas	$213M	MPM BioImpact, Wellcome & 14 others	62/100
5th	Latigo Biotherapeutics 2019, Thousand Oaks (United States), Public	Developer of non-opioid pain medicines for central nervous system	$322M	Foresite Capital, Qatar Investment Authority ... & 11 others	62/100
6th	Foresee Pharmaceuticals 2011, Taipei (Taiwan), Public	Developer of injectables and NCEs for cancer and chronic diseases	$32.5M	CDIB Capital Group, Vivo Capital & 4 others	61/100
7th	Quince Therapeutics 2012, San Francisco (United States), Public	Developer of therapeutics for orthopedic diseases	$108M	Pfizer Venture Investments, Balyasny Asset Management ... & 27 others	61/100
8th	Collegium Pharma 2002, Canton (United States), Public	Developer of therapeutics for chronic pain management	$103M	Longitude Capital, Skyline Ventures & 9 others	60/100
9th	Heron Therapeutics 1983, Redwood City (United States), Public	Pharmaceutical company focused on acute care and oncology with innovative therapies	-	Deep Track Capital, Rubric Capital & 9 others	59/100
10th	Osteal Therapeutics 2013, San Clemente (United States), Series D	Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections	$126M	Johnson & Johnson Innovation – JJDC, Huimei Capital ... & 7 others	59/100
94th	Slate Medicines 2026, Raleigh (United States), Series A	Developer of therapeutics for the treatment of migraine and other headache disorders	$130M	Foresite Capital, RA Capital Management & 1 others	39/100